Stockscreener 앱 받기
5.05
1.94%
-0.10
시간 외 거래:
5.11
0.06
+1.19%
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire
Humacyte StockInvestors of Humacyte Encouraged to Contact Kehoe Law Firm, P.C.HUMA - AccessWire
Revisiting Humacyte (NASDAQ:HUMA) - Seeking Alpha
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Humacyte's SWOT analysis: HAV tech stock poised for growth amid challenges - Investing.com Canada
(HUMA) Trading Signals - Stock Traders Daily
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte (NASDAQ:HUMA) Stock Price Down 2.9%Here's Why - MarketBeat
Humacyte reports positive trial results for hemodialysis access - Investing.com India
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
Humacyte reports positive trial results for hemodialysis access By Investing.com - Investing.com UK
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire Inc.
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA) - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024 - The Manila Times
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Humacyte Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - The Globe and Mail
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors - MSN
TD Cowen reaffirms Buy rating on Humacyte stock, believes FDA observations are resolved - Investing.com
Humacyte (NASDAQ:HUMA) Shares Gap UpTime to Buy? - MarketBeat
BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Piper Sandler maintains neutral on Humacyte - Investing.com
Humacyte, Inc. (NASDAQ:HUMA) Sees Large Increase in Short Interest - MarketBeat
Humacyte (NASDAQ:HUMA) Trading 6.5% HigherHere's What Happened - MarketBeat
When (HUMA) Moves Investors should Listen - Stock Traders Daily
‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab - The Wall Street Journal
AQR Capital Management LLC Grows Stock Position in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Given Buy Rating at Benchmark - MarketBeat
Millennium Management LLC Purchases 1,334,641 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
Humacyte Launches $30M Stock and Warrants Offering - Yahoo Finance
Humacyte stock outlook steady as TD Cowen points to FDA progress and facility inspection - Investing.com Canada
Humacyte to sell 5.68M shares at $5.28 in registered direct offering - TipRanks
Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) PT at $9.80 - MarketBeat
Marshall Wace LLP Purchases 450,031 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte secures $30 million through stock and warrants sale By Investing.com - Investing.com South Africa
Humacyte prices $30M securities offering - MSN
Humacyte secures $30 million through stock and warrants sale - Investing.com India
Humacycle Ekes up on Share Offering - Baystreet.ca
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering - The Manila Times
Humacyte (NASDAQ:HUMA) Stock Price Up 8.2% - MarketBeat
Renaissance Technologies LLC Purchases 524,600 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
TD Cowen maintains Buy rating on Humacyte with $10 target By Investing.com - Investing.com Australia
TD Cowen maintains Buy rating on Humacyte with $10 target - Investing.com India
Humacyte's SWOT analysis: HAV tech drives stock's potential amid challenges - Investing.com
1.11%
0.26%
자본화:
|
볼륨(24시간):